Get the Stockscreener App
23.01
3.21%
-0.788
Elanco Animal Health Inc stock is traded at $23.01, with a volume of 2.25M.
It is down -3.21% in the last 24 hours and up +5.18% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$23.80
Open:
$23.76
24h Volume:
2.25M
Relative Volume:
0.43
Market Cap:
$11.43B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
57.53
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+1.79%
1M Performance:
+5.18%
6M Performance:
+59.19%
1Y Performance:
+95.21%
1-Day Range:
$23.00
$23.81
1-Week Range:
$22.00
$23.89
52-Week Range:
$8.02
$23.89
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.01 | 11.83B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
126.88 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.88 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.06 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.38 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
48.87 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Assessing Elanco Animal Health (ELAN) Valuation After Befrena Approval And Turnaround Progress - Yahoo Finance
Veterinary Pain Management Drugs Market to hit US$ 3.00 Billion - openPR.com
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and Ascendis Pharma (ASND) - The Globe and Mail
Elanco Animal Health stock hits 52-week high at 23.71 USD - Investing.com Canada
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Finviz
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
3 Reasons to Avoid ELAN and 1 Stock to Buy Instead - Finviz
On-Farm Veterinary Diagnostic Solutions Market Booming with - openPR.com
Dogs Vaccines Market Strong Growth: New Report Highlights - openPR.com
Elanco Animal Health Inc (ELAT) Fundamental Analysis - Meyka
Breaking News - Today's Veterinary Business
ELAN SEC FilingsElanco Animal Health 10-K, 10-Q, 8-K Forms - Stock Titan
Elanco (ELAN) Gains USDA Approval for Befrena Injections - GuruFocus
Elanco (ELAN) Gains USDA Approval for New Canine Dermatology Tre - GuruFocus
Elanco gains approval of Befrena for canine dermatitis - Seeking Alpha
Elanco receives USDA approval for canine dermatitis treatment By Investing.com - Investing.com Canada
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis - PR Newswire
Voya Investment Management LLC Sells 2,335,093 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) CEO Jeffrey Simmons reports new deferred stock units - Stock Titan
Elanco (ELAN) EVP reports new deferred stock units award - Stock Titan
Targets Report: Will Elanco Animal Health Incorporated 5EA stock outperform value peers2025 EndofYear Setup & Free Low Drawdown Momentum Trade Ideas - moha.gov.vn
Yousif Capital Management LLC Boosts Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
EBITDA per share of Elanco Animal Health, Inc. – FWB:5EA - TradingView — Track All Markets
Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
Exchange Traded Concepts LLC Acquires Shares of 262,281 Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Earnings Notes - Trefis
Elanco Animal Health Inc (ELAN) director gifts 60,000 shares - Stock Titan
Elanco Animal Health working to combat New World screwwrorm - norfolkneradio.com
Oasis of Zen - Exhibitor Online
Middle East And Africa Animal Healthcare Market Forecast - openPR.com
Jim Cramer on Elanco Animal Health: "They Are Doing Everything Right" - Finviz
How Conditional FDA Approval of Credelio Quattro-CA1 Could Impact Elanco Animal Health (ELAN) Investors - Yahoo Finance
Jim Cramer on Elanco Animal Health: “They Are Doing Everything Right” - Yahoo Finance
Douglas Lane & Associates LLC Cuts Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (FRA:5EA) EV-to-OCF : 22.34 (As of Dec. 21, 2025) - GuruFocus
Does Elanco’s 85% 2025 Rally Match Its Long Term Valuation Prospects? - Yahoo Finance
Veterinary Medicine Market Size to Hit USD 98.51 Billion by 2033, Growing at a CAGR of 8.11%SNS Insider - GlobeNewswire
Wall Street Zen Downgrades Elanco Animal Health (NYSE:ELAN) to Buy - MarketBeat
Is Elanco Animal Health Incorporated stock dividend yield sustainableJuly 2025 Levels & Risk Controlled Swing Alerts - ulpravda.ru
Is Elanco Animal Health Incorporated stock a contrarian opportunityTrade Ideas & Weekly High Potential Stock Alerts - Улправда
Stifel maintains Buy rating on Elanco Animal Health stock with $27 price target - Investing.com Canada
Will Elanco Animal Health Incorporated stock benefit from automationEarnings Summary Report & AI Enhanced Trading Signals - Bölüm Sonu Canavarı
Elanco CEO Bites Off More Shares of Fast-Rising Stock - Barron's
Is Elanco Animal Health Incorporated (5EA) stock positioned for digital growth eraTrade Risk Assessment & Target Return Focused Picks - DonanımHaber
Companion Animal Vaccine Market is Going to Boom: New Report - openPR.com
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Steve Cohen, Citadel Investment Group, Elliott Management, Altai Capital, Elanco Animal Health Inc (ELAN), NVIDIA Corp (NVDA), and More - Insider Monkey
Elanco focused on production animals - norfolkneradio.com
Elanco Animal Health (NYSE:ELAN) Price Target Raised to $22.00 - MarketBeat
FDA conditionally approves Elanco’s treatment for screwworm in dogs By Investing.com - Investing.com Australia
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):